Cargando…
Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study
BACKGROUND AND OBJECTIVES: Topiroxostat, a selective xanthine oxidoreductase inhibitor, is used for the management of hyperuricemic patients with or without gout in Japan. Accumulating evidence has demonstrated the efficacy of topiroxostat for the treatment of hyperuricemia with or without gout. How...
Autores principales: | Ishikawa, Tomohiko, Maeda, Tatsushi, Hashimoto, Teruo, Nakagawa, Tetsuya, Ichikawa, Kazuhito, Sato, Yasushi, Kanno, Yoshihiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452866/ https://www.ncbi.nlm.nih.gov/pubmed/32621143 http://dx.doi.org/10.1007/s40261-020-00941-3 |
Ejemplares similares
-
The Effects of Topiroxostat, a Selective Xanthine Oxidoreductase Inhibitor, on Arterial Stiffness in Hyperuricemic Patients with Liver Dysfunction: A Sub-Analysis of the BEYOND-UA Study
por: Fujishima, Yuya, et al.
Publicado: (2023) -
Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout
por: Hosoya, Tatsuo, et al.
Publicado: (2018) -
Influence of xanthine oxidoreductase inhibitor, topiroxostat, on body weight of diabetic obese mice
por: Nakamura, Takashi, et al.
Publicado: (2021) -
Renoprotective Effect of Xanthine Oxidase Inhibitor, Topiroxostat
por: Katsuyama, Hisayuki, et al.
Publicado: (2019) -
Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout
por: Hosoya, Tatsuo, et al.
Publicado: (2014)